Investigational drug · Phase 3
GST-HG141
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Hepatitis b, Chronic Hepatitis B.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "GST-HG141"
First trial start
2025
Jul 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GST-HG141", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis b
- Chronic Hepatitis B
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "GST-HG141" as an intervention, largest first.
- Phase IIIB Extension Clinical Trial of Efficacy and Safety of GST-HG141 (Nairevir) Combined With NAs in Chronic Hepatitis BPivotal-lookingNot yet recruiting
Fujian Akeylink Biotechnology Co., Ltd.Industry
NCT07588009 · 576 participants (planned) · Start Jun 26, 2026 · Primary completion Jan 11, 2028
Drug: GST-HG141 · For: Chronic Hepatitis b
- To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug TreatmentPivotal-lookingRecruiting
Fujian Akeylink Biotechnology Co., Ltd.Industry
NCT07090759 · 526 participants (planned) · Start Jul 24, 2025 · Primary completion Dec 1, 2026
Drug: GST-HG141; GST-HG141 Placebo · For: Chronic Hepatitis b
Sites: Hangzhou, China
- Study on the Tolerance and Pharmacokinetics of GST-HG141 TabletsPivotal-lookingStatus unknown
Fujian Cosunter Pharmaceutical Co. LtdIndustry
NCT04386915 · 104 participants (planned) · Start May 18, 2020 · Primary completion May 30, 2021
Drug: GST-HG141 tablets; Placebo · For: Hepatitis B
Sites: Changchun, China
- Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 TabletsCompleted
Fujian Akeylink Biotechnology Co., Ltd.Industry
NCT05637541 · 90 participants · Start Jan 3, 2023 · Primary completion Jul 24, 2024
Drug: GST-HG141 · For: Chronic Hepatitis b
Sites: Changchun, China
Fujian Akeylink Biotechnology Co., Ltd.Industry
NCT07709520 · 80 participants (planned) · Start Jul 10, 2026 · Primary completion Oct 1, 2026
Drug: GST-HG141; GST-HG131 and 1 more · For: Chronic Hepatitis B
Sites: Beijing, China
Fujian Cosunter Pharmaceutical Co. LtdIndustry
NCT04868981 · 30 participants · Start May 31, 2021 · Primary completion Feb 23, 2022
Drug: GST-HG141 tablets; Matching Placebos for GST-HG141 tablets · For: Hepatitis B
Sites: Changchun, China
Fujian Akeylink Biotechnology Co., Ltd.Industry
NCT07944482 · 24 participants (planned) · Start Jul 3, 2026 · Primary completion Dec 31, 2026
Drug: GST-HG141 · For: Chronic Hepatitis b
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II study.
Wang C, Kong F, Gao H, et al. · EClinicalMedicine 2025
- Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design.
Wu M, Mai J, Zhang H, et al. · Virol J 2024
- Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Capsid Assembly Modulator GST-HG141 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.
Li C, Wu M, Zhang H, et al. · Antimicrob Agents Chemother 2021
Also in development for Chronic Hepatitis b
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TQA3605Phase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B, HBV Infection With LLV
- HRS-5635Phase 32 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Chronic Hepatitis B, Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
- Peg-IFN-αpegylated interferonPhase 26 trials
Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic
- TVAX-008Phase 24 trials
Grand Theravac Life Sciences (Nanjing) Co., Ltd. · Chronic Hepatitis B, HBV Infection, Chronic Hepatitis B Virus
- HT-101Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- HT-102Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- NAsNucleoside analogs, acidPhase 23 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Hepatitis B, HBV Infection With LLV
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.